Author:
Tang Liansha,Wang Jialing,Lin Nan,Zhou Yuwen,He Wenbo,Liu Jiyan,Ma Xuelei
Abstract
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies, including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, have obtained unprecedented benefit in multiple malignancies. However, the immune response activation in the body organs could arise immune-related adverse events (irAEs). Checkpoint inhibitor colitis (CIC) is the most widely reported irAEs. However, some obscure problems, such as the mechanism concerning gut microbiota, the confusing differential diagnosis with inflammatory bowel disease (IBD), the optimal steroid schedule, the reintroduction of ICIs, and the controversial prognosis features, influence the deep understanding and precise diagnosis and management of CIC. Herein, we based on these problems and comprehensively summarized the relevant studies of CIC in patients with NSCLC, further discussing the future research direction of this specific pattern of irAEs.
Subject
Immunology,Immunology and Allergy
Reference245 articles.
1. Cancer Statistics, 2021 (Vol 71, Pg 7, 2021);Siegel;CA Cancer J Clin,2021
2. Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1;Cabezon-Gutierrez;Clin Lung Cancer,2021
3. Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines;Ettinger;J Natl Compr Cancer Netw,2019
4. Treatment Patterns and Outcomes Change in Early-Stage Non-Small Cell Lung Cancer in Octogenarians and Older: A SEER Database Analysis;Bei;Aging Clin Exp Res,2021
5. Beyond EGFR, ALK and ROS1: Current Evidence and Future Perspectives on Newly Targetable Oncogenic Drivers in Lung Adenocarcinoma;Lamberti;Crit Rev Oncol Hematol,2020
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献